Friday, 18 October 2024
  
Login

Australia's most trusted
source of pharma news

Friday, 18 October 2024
News

Competitive intelligence deal lands

Posted 17 October 2024 AM

A new partnership between Commercial Eyes and AI experts Opyl will offer rich competitive intelligence data including pinpointing the most promising therapies being trialled, likelihood of trial success, timelines to commercialisation and even the chances of an HTA victory.

The service agreement announced yesterday will allow Commercial Eyes to leverage Opyl's AI-driven platform called TrialKey to enhance market research and competitive intelligence for potentially more than 1,000 clients, including 75 per cent of the world's largest pharmaceutical companies.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (17)

Access & Reimbursement (1)

Clinical & Medical, R&D (18)

Regulatory, Pharmacovigilance & QA (7)

Other (16)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.